Vor Biopharma Inc. announced on May 5, 2025, that it is winding down its clinical and manufacturing operations, leading to a workforce reduction of about 95% (147 employees) and estimated costs of approximately $19.3 million. The Chief Financial Officer and Chief Scientific Officer are set to be terminated on May 16, 2025, as part of this restructuring.